Could This Combo Therapy One Day Replace Chemotherapy?
Chemotherapy is a cancer treatment staple, but a recently published study suggests a combination of two treatments could provide the same benefit as chemotherapy with possibly far fewer side effects.
1 Small-Cap Biotech Stock to Buy and Hold For the Next 10 Years
Small cap biotech stocks have a lot of inherent risk, but if you can snag a winner your returns could double many times over. Here's one small-cap biotech stock you can consider buying and holding for the next 10 years.
3 Little-Known Biotechs Working On Potential Blockbusters
These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.
This Tiny Biotech Offers Up New Hope for Parkinson's Disease Patients
Phase 1 trial results for Prothena Corporation's PRX-002 could indicate that this drug may help treat Parkinson's disease someday.
Why ImmunoGen Inc. is Soaring Higher Today
Takeda Pharmaceutical has licensed ImmunoGen's antibody-drug conjugate technology.
This Market Could Grow 6250% in 10 Years
With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.
Dividend Stocks: 2 to Avoid, 1 to Buy
Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.
Why Prothena Corporation Plc is Soaring Higher Today
Results for Prothena's early-stage Parkinson's disease drug, PRX-002, have sent shares surging.
Why Inovio Pharmaceuticals Inc. Shot Higher Today
Despite reporting a net loss, Inovio's research pipeline opportunity boosts shares.
Why Exelixis, Inc. Shares Skyrocketed 57% in February
Exelixis shares soared in February as shareholders await two key catalysts.